TY - JOUR
T1 - Association between cardiac troponin I and mortality in patients with COVID-19
AU - Salvatici, Michela
AU - Barbieri, Barbara
AU - Cioffi, Sara Maria Giulia
AU - Morenghi, Emanuela
AU - Leone, Francesco Paolo
AU - Maura, Federica
AU - Moriello, Giuseppe
AU - Sandri, Maria Teresa
N1 - Funding Information:
The authors acknowledge all medical team for their clinical activities in the diagnosis and treatment of COVID-19. The authors thank the staff of the laboratory for assistance through test performance and data collection.
Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Background: Severe pneumonia is pathological manifestation of Coronavirus Disease 2019 (COVID-19), however complications have been reported in COVID-19 patients with a worst prognosis. Aim of this study was to evaluate the role of high sensitivity cardiac troponin I (hs-TnI) in patients with SARS-CoV-2 infection. Methods: we retrospectively analysed hs-TnI values measured in 523 patients (median age 64 years, 68% men) admitted to a university hospital in Milan, Italy, and diagnosed COVID-19. Results: A significant difference in hs-TnI concentrations was found between deceased patients (98 patients) vs discharged (425 patients) [36.05 ng/L IQR 16.5–94.9 vs 6.3 ng/L IQR 2.6–13.9, p < 0.001 respectively]. Hs-TnI measurements were independent predictors of mortality at multivariate analysis adjusted for confounding parameters such as age (HR 1.004 for each 10 point of troponin, 95% CI 1.002–1.006, p < 0.001). The survival rate, after one week, in patients with hs-TnI values under 6 ng/L was 97.94%, between 6 ng/L and the normal value was 90.87%, between the normal value and 40 ng/L was 86.98, and 59.27% over 40 ng/L. Conclusion: Increase of hs-TnI associated with elevated mortality in patients with COVID-19. Troponin shows to be a useful biomarker of disease progression and worse prognosis in COVID-19 patients.
AB - Background: Severe pneumonia is pathological manifestation of Coronavirus Disease 2019 (COVID-19), however complications have been reported in COVID-19 patients with a worst prognosis. Aim of this study was to evaluate the role of high sensitivity cardiac troponin I (hs-TnI) in patients with SARS-CoV-2 infection. Methods: we retrospectively analysed hs-TnI values measured in 523 patients (median age 64 years, 68% men) admitted to a university hospital in Milan, Italy, and diagnosed COVID-19. Results: A significant difference in hs-TnI concentrations was found between deceased patients (98 patients) vs discharged (425 patients) [36.05 ng/L IQR 16.5–94.9 vs 6.3 ng/L IQR 2.6–13.9, p < 0.001 respectively]. Hs-TnI measurements were independent predictors of mortality at multivariate analysis adjusted for confounding parameters such as age (HR 1.004 for each 10 point of troponin, 95% CI 1.002–1.006, p < 0.001). The survival rate, after one week, in patients with hs-TnI values under 6 ng/L was 97.94%, between 6 ng/L and the normal value was 90.87%, between the normal value and 40 ng/L was 86.98, and 59.27% over 40 ng/L. Conclusion: Increase of hs-TnI associated with elevated mortality in patients with COVID-19. Troponin shows to be a useful biomarker of disease progression and worse prognosis in COVID-19 patients.
KW - cardiac troponin
KW - COVID-19
KW - hospitalization
KW - mortality
KW - serially measurements of hs-TnI
UR - http://www.scopus.com/inward/record.url?scp=85096625897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096625897&partnerID=8YFLogxK
U2 - 10.1080/1354750X.2020.1831609
DO - 10.1080/1354750X.2020.1831609
M3 - Article
C2 - 33003961
AN - SCOPUS:85096625897
VL - 25
SP - 634
EP - 640
JO - Biomarkers
JF - Biomarkers
SN - 1354-750X
IS - 8
ER -